Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are in early-stage testing. Odyssey Therapeutics aims to tap Wall Street to develop targeted drugs for immune ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Sionna Therapeutics (SION), which is developing drugs to treat cystic fibrosis, has filed to raise $100M through an initial public offering. While Sionna (SION) didn't disclose terms in its SEC filing ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...